Des concepts aux biomarqueurs

et innovations en médecine de précision

16 équipes de recherche,

9 plateformes, 3 biotechs hébergées

Nos outils à la pointe de la technologie,

au service de la recherche contre le cancer

Au coeur d'un campus dédié à la recherche appliquée sur le cancer...



Les équipes de recherche de l'IRCM
Les équipes de recherche de l'IRCM

L'Institut de Recherche en Cancérologie de Montpellier :
«Ensemble, repoussons les limites»


SEMINAIRE IRCM Vendredi 12 Mai à 14h


Centre de Recherche des Cordeliers, INSERM UMRS1138, Paris

"Beta-catenin signaling, metabolism and epigenetics: a node for theranostics in primary liver cancers"

contact : Florence Cammas (Inserm/CNRS)

En savoir plus

Seminaire Mabimprove Mercredi 22 Mars à 11h

Patrick LegembreDirector of Research Inserm - Laboratoire CRIBL ( Contrôle de la Réponse Immune B et Lymphoproliférations) - UMR CNRS 7276 - Inserm U1262 à l'Université de Limoges " Therapeutic molecules to counteract the chronic Inflammation and the metastatic dissemination mediated by FasL/Fas pair in triple negative breast cancer (TNBC)"Abstract : "FasL belongs to the TNF family and interacts with the “so-called” death receptor Fas to trigger apoptosis. FasL is a transmembrane ligand, which can be cleaved by metalloproteases to release a soluble factor. While the membrane-bound FasL is a potent inducer of apoptosis, its soluble counterpart fails to induce cell death but trigger pro-inflammatory signals promoting the migration of triple negative breast cancer cells. More recently, we found that the loss of Fas in TNBC cells engenders a potent pro-inflammatory NF-kB signaling pathway, which promotes the elimination of the cancer cells via the activation/recruitment of anti-tumor NK cells. Because Fas expression is maintained in breast cancer cells isolated from TNBC patients and is associated with a good prognosis, we now aim at identifying in a comprehensive manner the Fas-dependent molecular mechanism controlling NF-kB in these TNBC cells." Contact : Nathalie Bonnefoy
En savoir plus

SEMINAIRE IRCM Jeudi 30 Mars de 14h à 15h


Vizgen, MEng, MBA, Regional Account Manager

Decipher Tissue Complexity with Spatial Genomics: Single Cell Spatially Resolved Transcriptomic Imaging with MERSCOPE Powered by MERFISH

contact : Laurent Le Cam (Inserm)

Biological systems are composed of numerous cell types, intricately organized to form functional tissues and organs. While recent advancements in genomics technologies have made it possible to characterize cell types through careful analysis of the transcriptome, they are unable to resolve how gene expression and cell types are spatially arranged. In this presentation, we introduce you to Vizgen’s all-in-one in situ genomics platform MERSCOPE, which enables the direct profiling of the spatial organization of intact tissue with genomic scale
throughput. The instrument, the MERFISH chemistry and use cases will be presented as well.


En savoir plus

Offre de poste d'ingénieur d'étude

Publié le 20/02/2023Patrick Jouandin, équipe Interactions métabolisme-épigénétique chez la Drosophile, jeune chef d’équipe ATIP-AVENIRCDD 12 mois renouvelableMORE...
En savoir plus

Postdoctoral position available: metabolism-epigenetics interplay in Drosophila

Publié le 20/02/23 Patrick Jouandin lab, young ATIP-AVENIR investigator, Montpellier Cancer Research Institute. Exciting projects,state-of-the-art technologies, friendly and dynamic scientific environment, translational research. ATIP-AVENIR funded position, 12 months + 12 month. MORE...
En savoir plus



Institut Gustave Roussy (IGR)-Paris

"Myeloid Cell Heterogeneity"

contact Julie Constanzo (ICM)

Florent Ginhoux is graduated in Biochemistry from the University Pierre et Marie CURIE (UPMC), Paris VI, obtained a Masters degree in Immunology from the Pasteur Institute in 2000 and his PhD in 2004 from UPMC, Paris VI. As a postdoctoral fellow, he joined the Laboratory of Miriam Merad in the Mount Sinai School of Medicine (MSSM), New York, where he studied the ontogeny and the homeostasis of cutaneous dendritic cell populations, with a strong focus on Langerhans cells and Microglia. In 2008, he became an Assistant Professor in the Department of Gene and Cell Medicine, MSSM and member of the Immunology Institute of MSSM. He joined the Singapore Immunology Network (SIgN), A*STAR in May 2009 as a Junior Principal Investigator and became Senior Principal Investigator in 2014. He joined the EMBO Young Investigator (YIP) program in 2013 and is a Web of Science Highly Cited Researcher since 2016. He is also an Adjunct Visiting Associate Professor in the Shanghai Immunology Institute, Jiao Tong University, in Shanghai, China since 2015 and Adjunct Associate Professor in the Translational Immunology Institute, SingHealth and Duke NUS, Singapore since 2016. He is now a Laboratory Director in Gustave Roussy focusing on pediatric cancers and the role of myeloid cells in tumor progression and became an EMBO member in 2022.

En savoir plus

Postdoctoral position available: RNA based nanovaccine for oncoimmunology.

Publié le 06/02/2023Offer: The laboratory of Dr Nathalie Bonnefoy, Immunity and Cancer team, at the research cancer instituteof Montpellier (IRCM, INSERM U1194: is looking for a full-time postdoctoral researchfellow to take on an exciting highly translational project to innovate in anti-cancer RAN based vaccine in thecontext of a European consortium project. The position is offered for 24 months with a possible reconduction for 1 year; selected candidate will workunder the supervision of Dr Julien Faget.Keywords: Neutrophil, lung cancer, immunotherapy, single-cell multi-omics, epigenetics, image masscytometry, genetic engineered mouse models  More...
En savoir plus

Postdoctoral position available: single-cell multi-omics in oncoimmunology.

Publié le 06/02/2023Offer: The laboratory of Dr Nathalie Bonnefoy, Immunity and Cancer team, at the research cancerinstitute of Montpellier (IRCM, INSERM U1194: is looking for a full-timepostdoctoral research fellow to take on an exciting highly translational project to decipher tumorpromoting neutrophils biogenesis in non-small cell lung cancer patients and mouse models.The position is offered for 24 months with a possible reconduction for 1 year; selected candidate willwork under the supervision of Dr Julien Faget.Keywords: Neutrophil, lung cancer, immunotherapy, single-cell multi-omics, epigenetics, image masscytometry, genetic engineered mouse models  More...
En savoir plus


DIMITRIS VLACHAKISAssociate Professor in Genetics @Biotech, AUA & Head of Dark DNA groupMedical School of Athens University, Greece"Artificial intelligence and Machine Learning turning the page on rational drug design”contact : Andrei TURTOI (Inserm)Why is so hard to design or discover a new drug nowadays? Is it because all the “easy” ones have been discovered? Is it because new regulations for taking a new candidate drug through clinical trials are too strict? It is because it is so time consuming and very expensive business indeed? Or is it just that the tools that have been used in this field are outdated and need to be refreshed? In this direction, novel Artificial Intelligence and Machine Learning pipelines are being designed by the merging of a repertoire of different scientific disciplines. Medicinal chemistry meets informatics, mathematics, biology, translational medicine, genetics and big data science and the result is simply amazing and very promising! There is new hope for drugs for cancer, autoimmune diseases, neurodegenerative diseases, inflammation and even rare diseases under the prism of precision medicine. Those new techniques and recent major scientific breakthroughs pave the way towards the development and establishment of the novel holistic drug design stratagems of tomorrow. However, even though it is clear that teaching an old dog new tricks is possible, it looks like it may not happen overnight. 
En savoir plus

Le mot de la Directrice

«Ensemble, repoussons les limites»

«En à peine 20 ans, l'Institut de Recherche en Cancérologie de Montpellier (IRCM U1194) a su hisser sa recherche au meilleur niveau international dans le domaine de la cancérologie fondamentale et appliquée, recherche réalisée en étroite collaboration avec les services cliniques du Centre de Lutte Contre le Cancer de Montpellier (ICM: l’Institut du Cancer de Montpellier ), et des partenaires industriels. Sous la tutelle conjointe de l'Inserm, de l'ICM et de l'Université de Montpellier, l'IRCM rassemble aujourd'hui plus de 240 personnes, chercheurs, cliniciens, techniciens et étudiants, organisés en 16 équipes de recherche qui s'appuient sur des plateaux techniques performants et des services de soutien compétents. Dans un domaine de recherche extrêmement compétitif et en évolution toujours plus rapide, notre plus grand défi est de garder une longueur d’avance. Pour cela nous continuerons à structurer la recherche sur le cancer à Montpellier, à rechercher l’excellence et à accélérer l’innovation et le transfert au patient pour in fine contribuer à vaincre les innombrables formes différentes de cancer. Ensemble, repoussons les limites.»

Nathalie Bonnefoy, Directrice de l'IRCM

Le mot de la Directrice

Principales publications

Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol J-L, Calvayrac O, Moll H, Glasson Y, Pirot N, Turtoi A, Cañamero M, Wong K-K, Yarden Y, Casanova E, Soria J-C, Colinge J, Siebel C, Favre G, Paz-Ares L, Maraver A Notch inhibition overcomes resistance to Tyrosine Kinase Inhibitors in EGFR-driven lung adenocarcinoma. J. Clin. Invest.. Oct 31, 2019. doi:10.1172/JCI126896

Combes E, Andrade A, Tosi D, Michaud H-A, Coquel F, Desigaud D, Jarlier M, Coquelle A, Pasero P, Bonnefoy N, Martineau P, Del Rio M, Beijersbergen R, Vezzio-Vie N Inhibition of Ataxia-Telangiectasia Mutated and RAD3-related (ATR) overcomes oxaliplatin resistance and promotes anti-tumor immunity in colorectal cancer. Cancer Res.. Apr 15, 2019. doi:10.1158/0008-5472.CAN-18-2807

Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz L, Roger P, Guiu S, Derocq D, Robin G, Michaud H-A, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget J-P, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer. 2019;7(1):29. doi:10.1186/s40425-019-0498-z

Ladjohounlou R, Lozza C, Pichard A, Constanzo J, Karam J, Le Fur P, Deshayes E, Boudousq V, Paillas S, Busson M, Le Blay M, Jarlier M, Marcatili S, Bardiès M, Bruchertseifer F, Morgenstern A, Torgue J, Navarro-Teulon I, Pouget J-P Drugs that modify cholesterol metabolism alter the p38/JNK-mediated targeted and non-targeted response to alpha and Auger radioimmunotherapy. Clin. Cancer Res.. May 06, 2019. doi:10.1158/1078-0432.CCR-18-3295

Perrot I, Michaud H-A, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, Jecko D, Becquart O, Rispaud-Blanc H, Gauthier L, Rossi B, Chanteux S, Gourdin N, Amigues B, Roussel A, Bensussan A, Eliaou J-F, Bastid J, Romagné F, Morel Y, Narni-Mancinelli E, Vivier E, Paturel C, Bonnefoy N Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. Cell Rep. 2019;27(8):2411-2425.e9. doi:10.1016/j.celrep.2019.04.091

Forest E, Logeay R, Géminard C, Kantar D, Frayssinoux F, Heron-Milhavet L, Djiane A The apical scaffold big bang binds to spectrins and regulates the growth of Drosophila melanogaster wing discs. J. Cell Biol.. 2018;217(3):1047-1062. doi:10.1083/jcb.201705107

Arena G, Cissé M, Pyrdziak S, Chatre L, Riscal R, Fuentes M, Arnold J, Kastner M, Gayte L, Bertrand-Gaday C, Nay K, Angebault-Prouteau C, Murray K, Chabi B, Koechlin-Ramonatxo C, Orsetti B, Vincent C, Marine J-C, Etienne-Manneville S, Bernex F, Lombès A, Cameron C, Dubouchaud H, Ricchetti M, Linares L, Le Cam L Mitochondrial MDM2 Regulates Respiratory Complex I Activity Independently of p53. Mol. Cell. 2018;69(4):594-609.e8. doi:10.1016/j.molcel.2018.01.023

Leconet W, Chentouf M, du Manoir S, Chevalier C, Sirvent A, Aït-Arsa I, Busson M, Jarlier M, Radosevic-Robin N, Theillet C, Chalbos D, Pasquet J-M, Pèlegrin A, Larbouret C, Robert B Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis. Clin. Cancer Res.. 2017;23(11):2806-2816. doi:10.1158/1078-0432.CCR-16-1316

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés